M. Manoharan

Molecular Biology · 2004–2023

A researcher in the Science corpus: 18 papers; trusts 4 researchers and is trusted by 6 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 162 citations into it; #7,832 of 17,773 by trust here, #615 by citations
• Cancer Research — 65 citations into it; #807 of 1,780 by trust here, #87 by citations

Whom M. Manoharan trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Eric F. Pettersen
2. Sayda M. Elbashir
3. David A. Case
4. Benjamin P. Lewis

Who trusts M. Manoharan overall

1. Phillip A. Sharp
2. R. Juliano
3. John J. Rossi
4. Eva van Rooij
5. Carlo Maria Croce
6. David P. Bartel

Papers from M. Manoharan's perspective

Ordered by how strongly the researchers M. Manoharan trusts endorse each paper. Same corpus, a different order for every researcher.

1. Expression profiling reveals off-target gene regulation by RNAi
2. Cleavage of Scarecrow-like mRNA Targets Directed by a Class of Arabidopsis miRNA (Science)
3. RNA interference is mediated by 21- and 22-nucleotide RNAs. (Genes & Development)
4. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics (Nature Biotechnology)
5. Functional siRNAs and miRNAs exhibit strand bias. (Cell)
6. Inhibition of respiratory viruses by nasally administered siRNA (Nature Medicine)
7. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. (RNA: A publication of the RNA Society)
8. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
9. Activation of the interferon system by short-interfering RNAs (Nature Cell Biology)
10. Molecular biology of PCSK9: its role in LDL metabolism. (TIBS -Trends in Biochemical Sciences. Regular ed)

Their papers

• Silencing of microRNAs in vivo with ‘antagomirs’ (2005) — 4,108 citations
• Mechanisms and optimization of in vivo delivery of lipophilic siRNAs (2007) — 956 citations
• A combinatorial library of lipid-like materials for delivery of RNAi therapeutics (2008) — 1,181 citations
• Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs (2004) — 2,198 citations
• A viral microRNA functions as an orthologue of cellular miR-155 (2007) — 613 citations
• RNAi-mediated gene silencing in non-human primates (2006) — 1,368 citations
• Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. (2010) — 955 citations
• Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 (2005) — 1,298 citations
• Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo (2012) — 1,185 citations
• Rational design of cationic lipids for siRNA delivery (2010) — 1,657 citations
• Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates (2008) — 660 citations
• RNAi therapeutics: a potential new class of pharmaceutical drugs (2006) — 1,039 citations
• Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. (2014) — 1,018 citations
• Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown (2015) — 602 citations
• The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs (2019) — 1,342 citations
• Chemistry, structure and function of approved oligonucleotide therapeutics (2023) — 637 citations
• Molecularly Self-Assembled Nucleic Acid Nanoparticles for Targeted In Vivo siRNA Delivery (2012) — 1,017 citations
• miR-181a is an intrinsic modulator of T cell sensitivity and selection. (2007) — 1,235 citations